8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Feb 6, 2026·SEC
Hologic, Inc.(HOLX)Earnings, Financials & Key Ratios
HOLX•NASDAQ
30.5× P/E·Price updated May 19, 2026
AboutHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.Show more
- Revenue$4.1B+1.7%
- EBITDA$1.01B-14.9%
- Net Income$566M-28.3%
- EPS (Diluted)2.49-25.0%
- Gross Margin60.99%+10.3%
- EBITDA Margin24.73%-16.4%
- Operating Margin17.42%-20.5%
- Net Margin13.8%-29.6%
- ROE11.12%-28.6%
HOLX Key Insights
Hologic, Inc. (HOLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 22.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 4.2% through buybacks
- ✓Healthy 5Y average net margin of 20.9%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 12.7% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HOLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HOLX Price & Volume
Hologic, Inc. (HOLX) stock price & volume — 10-year historical chart
Loading chart...
HOLX Growth Metrics
Hologic, Inc. (HOLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.25%
5 Years1.66%
3 Years-5.53%
TTM2.16%
Profit CAGR
10 Years15.7%
5 Years-12.69%
3 Years-24.26%
TTM-26.9%
EPS CAGR
10 Years18.66%
5 Years-9.97%
3 Years-21.41%
TTM-24.29%
Return on Capital
10 Years13.35%
5 Years17.13%
3 Years9.39%
Last Year8.84%
HOLX Recent Earnings
Hologic, Inc. (HOLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Jan 29, 2026Metric
Actual
Est
EPS
$1.04-4.6%
$1.09
Rev
$1.0B-2.2%
$1.1B
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$1.13+2.7%
$1.10
Rev
$1.0B+1.5%
$1.0B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$1.08+2.9%
$1.05
Rev
$1.0B-1.0%
$1.0B
Q2 2025
May 1, 2025Metric
Actual
Est
EPS
$1.03+1.0%
$1.02
Rev
$1.0B+0.5%
$1.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Jan 29, 2026 | $1.04vs $1.09-4.6% | $1.0Bvs $1.1B-2.2% |
| Q4 2025 | Nov 3, 2025 | $1.13vs $1.10+2.7% | $1.0Bvs $1.0B+1.5% |
| Q3 2025 | Jul 30, 2025 | $1.08vs $1.05+2.9% | $1.0Bvs $1.0B-1.0% |
| Q2 2025 | May 1, 2025 | $1.03vs $1.02+1.0% | $1.0Bvs $1.0B+0.5% |
Based on last 12 quarters of dataView full earnings history →
HOLX Peer Comparison
Hologic, Inc. (HOLX) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 DXCM | 27.96B | 72.47 | 34.67 | 15.6% | 19.31% | 33.83% | 0.51 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 | |
 GH | 17.47B | 131.78 | -39.69 | 32.88% | -40.1% | |||
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 |
Compare HOLX vs Peers
Hologic, Inc. (HOLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HOLX Income Statement
Hologic, Inc. (HOLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.06B | 3.22B | 3.37B | 3.78B | 5.63B | 4.86B | 4.03B | 4.03B | 4.1B | 4.13B |
Revenue Growth % | 7.98% | 5.2% | 4.64% | 12.15% | 49.14% | -13.66% | -17.12% | -0% | 1.74% | 2.16% |
Cost of Goods Sold | 1.44B | 1.52B | 2.06B | 1.55B | 1.84B | 1.87B | 1.96B | 1.8B | 1.6B | 1.95B |
COGS % of Revenue | 47.01% | 47.27% | 61.15% | 41.02% | 32.61% | 38.36% | 48.6% | 44.72% | 39.01% | - |
Gross Profit | 1.62B▲ 0% | 1.7B▲ 4.7% | 1.31B▼ 22.9% | 2.23B▲ 70.3% | 3.8B▲ 70.4% | 3B▼ 21.0% | 2.07B▼ 30.9% | 2.23B▲ 7.5% | 2.5B▲ 12.3% | 2.18B▲ 0% |
Gross Margin % | 52.99% | 52.73% | 38.85% | 58.98% | 67.39% | 61.64% | 51.4% | 55.28% | 60.99% | 52.82% |
Gross Profit Growth % | 3.69% | 4.67% | -22.9% | 70.29% | 70.41% | -21.03% | -30.89% | 7.55% | 12.27% | - |
Operating Expenses | 1.14B | 1.19B | 1.18B | 1.12B | 1.32B | 1.36B | 1.4B | 1.35B | 1.79B | 1.46B |
OpEx % of Revenue | 37.18% | 36.94% | 35.08% | 29.72% | 23.36% | 27.91% | 34.81% | 33.38% | 43.58% | - |
Selling, General & Admin | 841.9M | 910.7M | 897.2M | 840.3M | 994.4M | 1.04B | 987.6M | 994.8M | 1.07B | 1.07B |
SG&A % of Revenue | 27.52% | 28.3% | 26.64% | 22.25% | 17.66% | 21.35% | 24.5% | 24.68% | 26.09% | - |
Research & Development | 232.8M | 218.7M | 232.2M | 222.5M | 276.3M | 283.4M | 294.3M | 272.8M | 248.2M | 248.5M |
R&D % of Revenue | 7.61% | 6.8% | 6.9% | 5.89% | 4.91% | 5.83% | 7.3% | 6.77% | 6.05% | - |
Other Operating Expenses | 12.9M | 7.6M | 52M | 59.7M | 44.8M | 35.8M | 121.2M | 77.6M | 468.7M | 4M |
Operating Income | 1.37B▲ 0% | -237.9M▼ 117.4% | 134.4M▲ 156.5% | 1.1B▲ 722.2% | 2.48B▲ 124.5% | 1.64B▼ 33.9% | 668.4M▼ 59.2% | 882.6M▲ 32.0% | 714.3M▼ 19.1% | 721.6M▲ 0% |
Operating Margin % | 44.8% | -7.39% | 3.99% | 29.26% | 44.04% | 33.73% | 16.58% | 21.9% | 17.42% | 17.49% |
Operating Income Growth % | 149.76% | -117.36% | 156.49% | 722.17% | 124.46% | -33.87% | -59.25% | 32.05% | -19.07% | - |
EBITDA | 1.82B | 242.4M | 597.4M | 1.48B | 2.89B | 2.07B | 991.8M | 1.19B | 1.01B | 973.7M |
EBITDA Margin % | 59.48% | 7.53% | 17.74% | 39.22% | 51.26% | 42.57% | 24.61% | 29.57% | 24.73% | 23.6% |
EBITDA Growth % | 79.43% | -86.68% | 146.45% | 147.91% | 94.95% | -28.29% | -52.09% | 20.15% | -14.9% | -21.58% |
D&A (Non-Cash Add-back) | 449.2M | 480.3M | 463M | 376M | 406.9M | 430.1M | 323.4M | 309M | 299.8M | 252.1M |
EBIT | 1.38B | -269.9M | -116.9M | 1.12B | 2.45B | 1.68B | 787.2M | 987.2M | 723.9M | 761.8M |
Net Interest Income | -149.4M | -142.4M | -136.2M | -112.2M | -92.2M | -82.2M | 9.4M | -13.4M | 31.7M | -25.3M |
Interest Income | 3.8M | 6.3M | 4.6M | 4.3M | 1.4M | 12.9M | 120.5M | 108.7M | 74.4M | 69.9M |
Interest Expense | 153.2M | 148.7M | 140.8M | 116.5M | 93.6M | 95.1M | 111.1M | 122.1M | 42.7M | 95.2M |
Other Income/Expense | -139.7M | -180.7M | -296.3M | -103.1M | -119.2M | -52M | 7.7M | -17.5M | -33.1M | -58M |
Pretax Income | 1.23B▲ 0% | -418.6M▼ 134.0% | -95.3M▲ 77.2% | 1B▲ 1151.3% | 2.36B▲ 135.7% | 1.59B▼ 32.7% | 676.1M▼ 57.4% | 865.1M▲ 28.0% | 681.2M▼ 21.3% | 663.6M▲ 0% |
Pretax Margin % | 40.23% | -13.01% | -2.83% | 26.53% | 41.92% | 32.66% | 16.78% | 21.46% | 16.61% | 16.08% |
Income Tax | 475M | -307.3M | -55.1M | -108.6M | 491.4M | 286.2M | 220.1M | 75.6M | 115.5M | 119.7M |
Effective Tax Rate % | 38.6% | 73.41% | 57.82% | -10.84% | 20.81% | 18.02% | 32.55% | 8.74% | 16.96% | 18.04% |
Net Income | 755.5M▲ 0% | -111.3M▼ 114.7% | -40.2M▲ 63.9% | 1.12B▲ 2874.1% | 1.87B▲ 67.8% | 1.3B▼ 30.4% | 456M▼ 65.0% | 789.5M▲ 73.1% | 565.7M▼ 28.3% | 543.9M▲ 0% |
Net Margin % | 24.7% | -3.46% | -1.19% | 29.53% | 33.23% | 26.77% | 11.31% | 19.59% | 13.8% | 13.18% |
Net Income Growth % | 128.39% | -114.73% | 63.88% | 2874.13% | 67.82% | -30.43% | -64.98% | 73.14% | -28.35% | -26.9% |
Net Income (Continuing) | 755.5M | -111.3M | -203.6M | 1.11B | 1.87B | 1.3B | 456M | 789.5M | 565.7M | 543.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.64▲ 0% | -0.40▼ 115.2% | -0.15▲ 62.5% | 4.21▲ 2906.7% | 7.21▲ 71.3% | 5.13▼ 28.8% | 1.83▼ 64.3% | 3.32▲ 81.4% | 2.49▼ 25.0% | 2.41▲ 0% |
EPS Growth % | 127.59% | -115.15% | 62.5% | 2906.67% | 71.26% | -28.85% | -64.33% | 81.42% | -25% | -24.29% |
EPS (Basic) | 2.70 | -0.40 | -0.15 | 4.24 | 7.28 | 5.18 | 1.85 | 3.35 | 2.50 | - |
Diluted Shares Outstanding | 285.65M | 275.11M | 269.41M | 264.61M | 259.71M | 253.84M | 248.83M | 237.55M | 227.57M | 225.88M |
Basic Shares Outstanding | 279.81M | 275.11M | 269.41M | 262.73M | 257.05M | 251.53M | 246.77M | 235.72M | 227.19M | 224.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HOLX Balance Sheet
Hologic, Inc. (HOLX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.48B | 1.72B | 1.79B | 2.22B | 3.17B | 3.86B | 4.18B | 3.82B | 3.67B | 3.84B |
Cash & Short-Term Investments | 540.6M | 666.7M | 601.8M | 701M | 1.17B | 2.34B | 2.72B | 2.33B | 2.2B | 2.36B |
Cash Only | 540.6M | 666.7M | 601.8M | 701M | 1.17B | 2.34B | 2.72B | 2.16B | 1.96B | 2.17B |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 173.4M | 243.2M | 196.7M |
Accounts Receivable | 533.5M | 579.2M | 648.7M | 1.03B | 942.7M | 617.6M | 625.6M | 600.4M | 600.8M | 584.2M |
Days Sales Outstanding | 63.66 | 65.7 | 70.32 | 99.45 | 61.09 | 46.36 | 56.66 | 54.37 | 53.48 | 53.93 |
Inventory | 331.6M | 384.1M | 444.9M | 395.1M | 501.2M | 623.7M | 617.6M | 679.8M | 679.4M | 688.5M |
Days Inventory Outstanding | 84.18 | 92.16 | 78.86 | 93.11 | 99.61 | 122.04 | 115.08 | 137.66 | 155.05 | 131.15 |
Other Current Assets | 50.5M | 61.5M | 62.8M | 58.5M | 528.8M | 232.2M | 187.2M | 156.2M | 152M | 176M |
Total Non-Current Assets | 6.5B | 5.51B | 4.82B | 4.97B | 5.75B | 5.21B | 4.95B | 5.33B | 5.35B | 5.34B |
Property, Plant & Equipment | 472.8M | 478.2M | 470.9M | 572.2M | 648.3M | 550.5M | 579.7M | 630M | 653.7M | 568.3M |
Fixed Asset Turnover | 6.47x | 6.73x | 7.15x | 6.60x | 8.69x | 8.83x | 6.95x | 6.40x | 6.27x | 7.03x |
Goodwill | 3.17B | 2.53B | 2.56B | 2.66B | 3.28B | 3.24B | 3.28B | 3.44B | 3.64B | 3.65B |
Intangible Assets | 2.75B | 2.4B | 1.46B | 1.31B | 1.66B | 1.28B | 888.6M | 844.6M | 589.1M | 547.3M |
Long-Term Investments | 3M | 8.8M | 54.1M | 11.4M | 9.5M | 5.5M | 15.5M | 150.7M | 78.5M | 78.5M |
Other Non-Current Assets | 72.6M | 76M | 83.3M | 409M | 130.7M | 119.9M | 133.1M | 135.5M | 145.1M | 576.5M |
Total Assets | 7.98B▲ 0% | 7.23B▼ 9.4% | 6.61B▼ 8.6% | 7.2B▲ 8.8% | 8.92B▲ 24.0% | 9.07B▲ 1.7% | 9.14B▲ 0.8% | 9.16B▲ 0.2% | 9.01B▼ 1.5% | 9.18B▲ 0% |
Asset Turnover | 0.38x | 0.45x | 0.51x | 0.52x | 0.63x | 0.54x | 0.44x | 0.44x | 0.45x | 0.46x |
Asset Growth % | 9.06% | -9.38% | -8.57% | 8.84% | 23.96% | 1.7% | 0.75% | 0.18% | -1.54% | 0.75% |
Total Current Liabilities | 1.87B | 1.4B | 1.07B | 1.24B | 1.33B | 937.7M | 1.21B | 1.04B | 977.2M | 951.3M |
Accounts Payable | 166.6M | 192.2M | 186.5M | 178.8M | 215.9M | 197.7M | 175.2M | 203.8M | 193.4M | 201.1M |
Days Payables Outstanding | 42.29 | 46.12 | 33.06 | 42.13 | 42.91 | 38.68 | 32.64 | 41.27 | 44.14 | 37.3 |
Short-Term Debt | 1.15B | 599.7M | 271.4M | 324.9M | 313M | 15M | 287M | 37.5M | 2.9M | 9.3M |
Deferred Revenue (Current) | 171.2M | 172.9M | 179.5M | 186.1M | 198M | 186.5M | 199.2M | 212.9M | 199.7M | 796.6M |
Other Current Liabilities | 176.7M | 196M | 223.4M | 262.7M | 313.5M | 292.2M | 288.3M | 289M | 294.2M | 1.9M |
Current Ratio | 0.79x | 1.23x | 1.68x | 1.79x | 2.39x | 4.12x | 3.47x | 3.69x | 3.75x | 4.04x |
Quick Ratio | 0.61x | 0.95x | 1.26x | 1.47x | 2.01x | 3.45x | 2.95x | 3.03x | 3.06x | 3.32x |
Cash Conversion Cycle | 105.55 | 111.74 | 116.12 | 150.42 | 117.79 | 129.71 | 139.09 | 150.76 | 164.39 | 147.78 |
Total Non-Current Liabilities | 3.33B | 3.4B | 3.26B | 3.25B | 3.37B | 3.26B | 2.92B | 2.99B | 2.99B | 2.98B |
Long-Term Debt | 2.17B | 2.7B | 2.78B | 2.71B | 2.71B | 2.81B | 2.53B | 2.5B | 2.5B | 2.5B |
Capital Lease Obligations | 56.8M | 56.4M | 52.9M | 83M | 88.9M | 71.8M | 62.4M | 96.1M | 88.4M | 116.8M |
Deferred Tax Liabilities | 973.6M | 498.2M | 275.3M | 305.5M | 460.5M | 342.4M | 294.5M | 371.2M | 373.8M | 508.9M |
Other Non-Current Liabilities | 106.1M | 122.1M | 128.7M | 133.9M | 92.6M | 25.3M | 13.2M | 10.6M | 10.2M | 419M |
Total Liabilities | 5.19B | 4.8B | 4.33B | 4.49B | 4.7B | 4.2B | 4.12B | 4.03B | 3.97B | 3.94B |
Total Debt | 3.38B | 3.36B | 3.11B | 3.15B | 3.14B | 2.92B | 2.9B | 2.66B | 2.63B | 2.52B |
Net Debt | 2.84B | 2.7B | 2.51B | 2.45B | 1.97B | 582.1M | 181.6M | 497.8M | 667.3M | 352.3M |
Debt / Equity | 1.21x | 1.38x | 1.36x | 1.16x | 0.75x | 0.60x | 0.58x | 0.52x | 0.52x | 0.48x |
Debt / EBITDA | 1.86x | 13.87x | 5.21x | 2.13x | 1.09x | 1.41x | 2.93x | 2.23x | 2.59x | 2.59x |
Net Debt / EBITDA | 1.56x | 11.12x | 4.20x | 1.65x | 0.68x | 0.28x | 0.18x | 0.42x | 0.66x | 0.36x |
Interest Coverage | 9.03x | -1.82x | -0.83x | 9.60x | 26.23x | 17.70x | 7.09x | 8.09x | 16.95x | 8.00x |
Total Equity | 2.78B▲ 0% | 2.43B▼ 12.8% | 2.28B▼ 6.2% | 2.71B▲ 18.8% | 4.22B▲ 55.8% | 4.88B▲ 15.6% | 5.02B▲ 2.9% | 5.13B▲ 2.3% | 5.05B▼ 1.6% | 5.25B▲ 0% |
Equity Growth % | 29.96% | -12.78% | -6.16% | 18.79% | 55.82% | 15.59% | 2.89% | 2.25% | -1.6% | 1.44% |
Book Value per Share | 9.75 | 8.83 | 8.46 | 10.23 | 16.24 | 19.21 | 20.16 | 21.60 | 22.18 | 23.22 |
Total Shareholders' Equity | 2.78B | 2.43B | 2.28B | 2.71B | 4.22B | 4.88B | 5.02B | 5.13B | 5.05B | 5.25B |
Common Stock | 2.9M | 2.9M | 2.9M | 2.9M | 3M | 3M | 3M | 3M | 3M | 3M |
Retained Earnings | -2.38B | -2.49B | -2.69B | -1.57B | 298.3M | 1.6B | 2.06B | 2.85B | 3.41B | 3.59B |
Treasury Stock | -450.1M | -725.9M | -926M | -1.58B | -1.99B | -2.53B | -3.04B | -3.85B | -4.61B | -4.61B |
Accumulated OCI | -16.2M | -25.5M | -42.3M | -49.7M | -59.1M | -238.2M | -147.6M | -111.5M | -100.8M | -94.8M |
Minority Interest | 0 | 0 | 0 | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 |
HOLX Cash Flow Statement
Hologic, Inc. (HOLX) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 8.3M | 732.9M | 649.5M | 896.6M | 2.33B | 2.13B | 1.05B | 1.29B | 1.06B | 1.1B |
Operating CF Margin % | 0.27% | 22.78% | 19.29% | 23.74% | 41.38% | 43.71% | 26.08% | 31.89% | 25.78% | - |
Operating CF Growth % | -98.95% | 8730.12% | -11.38% | 38.04% | 159.92% | -8.78% | -50.55% | 22.26% | -17.75% | -39.26% |
Net Income | 755.5M | -111.3M | -40.2M | 1.11B | 1.87B | 1.3B | 456M | 789.5M | 565.7M | 543.9M |
Depreciation & Amortization | 449.2M | 480.3M | 463.1M | 376M | 406.9M | 430.1M | 323.4M | 309M | 299.8M | 295.4M |
Stock-Based Compensation | 68.2M | 65M | 62M | 83.3M | 65M | 66.7M | 79.6M | 82.3M | 84.3M | 81.1M |
Deferred Taxes | -357.2M | -477.3M | -231.7M | -94.4M | 0 | -166.2M | 0 | -72.1M | -141.6M | -123.2M |
Other Non-Cash Items | -804.2M | 802.4M | 557.6M | 57.5M | 21.4M | 38.9M | 189.2M | 92.4M | 269.3M | 295M |
Working Capital Changes | -103.2M | -26.2M | -161.3M | -636.3M | -34.4M | 454.2M | 3M | 84.1M | -20.4M | 5.6M |
Change in Receivables | -41.5M | -38.2M | -76.5M | -427.1M | 110.9M | 272.3M | -1.5M | 41M | 7.8M | 67.5M |
Change in Inventory | -11.6M | -50.6M | -63M | -25.3M | -84.1M | -136.6M | -4.9M | -47.4M | -1.3M | 26.2M |
Change in Payables | -10.6M | 23.9M | -5.5M | -4.9M | 0 | -14.4M | 0 | 22.2M | -11.3M | -39.7M |
Cash from Investing | 285.8M | -195.2M | -280.7M | -141.6M | -1.33B | -206.3M | -152.1M | -781M | -482.7M | -472.8M |
Capital Expenditures | -107.6M | -105.6M | -113.6M | -156.4M | -177.7M | -127.2M | -150.2M | -72.4M | -78.2M | -90.1M |
CapEx % of Revenue | 3.52% | 3.28% | 3.37% | 4.14% | 3.16% | 2.62% | 3.73% | 1.8% | 1.91% | 2.18% |
Acquisitions | 306.9M | -76.5M | -128.8M | 19.9M | -1.16B | -158.6M | -5M | -297.3M | -321.5M | -321.2M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -600K | -7.2M | -30.8M | -2.7M | 12.8M | 79.5M | 3.1M | -143.6M | -77.1M | -32.6M |
Cash from Financing | -309.2M | -404.8M | -431.5M | -659.9M | -529.8M | -756M | -483.2M | -1.11B | -777.2M | -250.9M |
Debt Issued (Net) | -138.4M | -145.5M | -260.4M | -31.5M | -111.9M | -212.3M | -19M | -291.3M | -39.8M | -30.5M |
Equity Issued (Net) | -200.1M | -275.8M | -200.1M | -653.6M | -457.3M | -542.1M | -498.8M | -797.3M | -714.1M | -209.6M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -200.1M | -275.8M | -200.1M | -653.6M | -457.3M | -542.1M | -498.8M | -835.1M | -752.9M | -235.8M |
Other Financing | 29.3M | 16.5M | 29M | 25.2M | 39.4M | -1.6M | 34.6M | -20M | -23.3M | -10.8M |
Net Change in Cash | -7.8M▲ 0% | 126.1M▲ 1716.7% | -64.9M▼ 151.5% | 99.2M▲ 252.9% | 469.3M▲ 373.1% | 1.17B▲ 149.1% | 416.2M▼ 64.4% | -595.5M▼ 243.1% | -200.7M▲ 66.3% | 385.9M▲ 0% |
Free Cash Flow | -99.3M▲ 0% | 627.3M▲ 731.7% | 535.9M▼ 14.6% | 740.2M▲ 38.1% | 2.15B▲ 190.8% | 2B▼ 7.2% | 901M▼ 54.9% | 1.15B▲ 27.1% | 920.1M▼ 19.6% | 999.6M▲ 0% |
FCF Margin % | -3.25% | 19.49% | 15.91% | 19.6% | 38.22% | 41.1% | 22.36% | 28.41% | 22.44% | 24.22% |
FCF Growth % | -114.42% | 731.72% | -14.57% | 38.12% | 190.83% | -7.16% | -54.92% | 27.08% | -19.64% | -10.37% |
FCF per Share | -0.35 | 2.28 | 1.99 | 2.80 | 8.29 | 7.87 | 3.62 | 4.82 | 4.04 | 4.43 |
FCF Conversion (FCF/Net Income) | 0.01x | -6.58x | -16.16x | 0.80x | 1.25x | 1.63x | 2.31x | 1.63x | 1.87x | 1.84x |
Interest Paid | 102.4M | 122.1M | 132.5M | 109.5M | 93.2M | 99.7M | 105.4M | 0 | 0 | 0 |
Taxes Paid | 867.8M | 178.2M | 180.6M | 265.9M | 0 | 36.2M | 0 | 137.9M | 0 | 0 |
HOLX Key Ratios
Hologic, Inc. (HOLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 30.67% | -4.27% | -1.71% | 44.73% | 54.04% | 28.63% | 9.22% | 15.56% | 11.12% | 11.01% |
Return on Invested Capital (ROIC) | 19.39% | -3.32% | 2.03% | 16.67% | 32.79% | 21.12% | 9.41% | 12.23% | 9.45% | 9.55% |
Gross Margin | 52.99% | 52.73% | 38.85% | 58.98% | 67.39% | 61.64% | 51.4% | 55.28% | 60.99% | 52.82% |
Net Margin | 24.7% | -3.46% | -1.19% | 29.53% | 33.23% | 26.77% | 11.31% | 19.59% | 13.8% | 13.18% |
Debt / Equity | 1.21x | 1.38x | 1.36x | 1.16x | 0.75x | 0.60x | 0.58x | 0.52x | 0.52x | 0.48x |
Interest Coverage | 9.03x | -1.82x | -0.83x | 9.60x | 26.23x | 17.70x | 7.09x | 8.09x | 16.95x | 8.00x |
FCF Conversion | 0.01x | -6.58x | -16.16x | 0.80x | 1.25x | 1.63x | 2.31x | 1.63x | 1.87x | 1.84x |
Revenue Growth | 7.98% | 5.2% | 4.64% | 12.15% | 49.14% | -13.66% | -17.12% | -0% | 1.74% | 2.16% |
Related:HOLX Dividend History·HOLX Revenue History·HOLX Price History·HOLX P/E History·HOLX Financial Ratios·HOLX Institutional Holders
HOLX SEC Filings & Documents
Hologic, Inc. (HOLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
HOLX Frequently Asked Questions
Hologic, Inc. (HOLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Hologic, Inc. (HOLX) reported $4.13B in revenue for fiscal year 2025. This represents a 4578% increase from $88.2M in 1996.
Hologic, Inc. (HOLX) grew revenue by 1.7% over the past year. Growth has been modest.
Yes, Hologic, Inc. (HOLX) is profitable, generating $543.9M in net income for fiscal year 2025 (13.8% net margin).
Dividend & Returns
Hologic, Inc. (HOLX) has a return on equity (ROE) of 11.1%. This is reasonable for most industries.
Hologic, Inc. (HOLX) generated $999.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.